- Home
- GFR vs ATXS Comparison
GFR vs ATXS Comparison
Compare GFR & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GFR
- ATXS
- Stock Information
- Founded
- GFR 2018
- ATXS 2008
- Country
- GFR Canada
- ATXS United States
- Employees
- GFR N/A
- ATXS N/A
- Industry
- GFR
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- GFR
- ATXS Health Care
- Exchange
- GFR Nasdaq
- ATXS Nasdaq
- Market Cap
- GFR 423.8M
- ATXS 401.2M
- IPO Year
- GFR N/A
- ATXS 2015
- Fundamental
- Price
- GFR $6.02
- ATXS $5.40
- Analyst Decision
- GFR Buy
- ATXS Strong Buy
- Analyst Count
- GFR 1
- ATXS 5
- Target Price
- GFR $10.50
- ATXS $26.60
- AVG Volume (30 Days)
- GFR 105.1K
- ATXS 285.8K
- Earning Date
- GFR 03-14-2025
- ATXS 03-11-2025
- Dividend Yield
- GFR N/A
- ATXS N/A
- EPS Growth
- GFR N/A
- ATXS N/A
- EPS
- GFR 1.18
- ATXS N/A
- Revenue
- GFR $549,712,963.00
- ATXS N/A
- Revenue This Year
- GFR $53.11
- ATXS N/A
- Revenue Next Year
- GFR $35.59
- ATXS N/A
- P/E Ratio
- GFR $4.97
- ATXS N/A
- Revenue Growth
- GFR 21.26
- ATXS N/A
- 52 Week Low
- GFR $4.82
- ATXS $5.24
- 52 Week High
- GFR $8.16
- ATXS $13.33
- Technical
- Relative Strength Index (RSI)
- GFR 61.92
- ATXS 30.54
- Support Level
- GFR $5.31
- ATXS $5.89
- Resistance Level
- GFR $5.77
- ATXS $6.52
- Average True Range (ATR)
- GFR 0.28
- ATXS 0.37
- MACD
- GFR 0.14
- ATXS -0.07
- Stochastic Oscillator
- GFR 92.35
- ATXS 7.80
About GFR Greenfire Resources Ltd.
Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The Company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.